Margreet Ausems

Margreet Ausems is a Full Professor at Utrecht University, affiliated with the Clinical Oncogenetics research group. Her work focuses on improving access to genetic care for cancer patients and their families, particularly in hereditary cancer syndromes such as BRCA1/2 and CHEK2 mutations. She leads studies on preventive surgical interventions (e.g., risk-reducing salpingo-oophorectomy) and their cardiovascular impacts, as well as psychosocial effects of cancer screening.

She holds roles in multiple advisory committees, including KWF Kankerbestrijding's KADI committee for research grant evaluations, the Prostaatkankerstichting's advisory board, and AstraZeneca's BRCA diagnostic expert group. Her research integrates clinical genetics, oncology, and public health to advance personalized cancer prevention strategies.

Her recent publications emphasize cohort studies (e.g., Hebon-CHEK2) and model validations (e.g., BOADICEA) for risk prediction in hereditary cancers. She collaborates internationally on projects like the European Familial Breast Cancer Studies (EUROBAC2).